Nanocarrier systems loaded with IR780, iron oxide nanoparticles and chlorambucil for cancer theragnostics

• Published in: Beilstein journal of nanotechnology 2024-02, Vol.15 (1), p.180-189
• Main Authors: Dang-Luong, Phuong-Thao, Nguyen, Hong-Phuc, Le-Tuan, Loc, Cao, Xuan-Thang, Tran-Anh, Vy, Quang, Hieu Vu
• Format: Article
• Language: English
• Subjects: cancer; chlorambucil; f127-folate; Full Research Paper; ir780; iron oxide nanoparticles; Nanoscience; Nanotechnology; plga; theragnostics
• ISSN: 2190-4286; 2190-4286
• DOI: 10.3762/bjnano.15.17

Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform. Therefore, formulating a nanocarrier system that could serve as theragnostic agent by using simple techniques would be an advantage during production. In this project, we aimed to develop a nanocarrier that can be loaded with the chemotherapeutic medication chlorambucil and magnetic resonance imaging agents (e.g., iron oxide nanoparticles and near-infrared fluorophore IR780) for theragnostics. Poly(lactic- -glycolic acid) was combined with the aforementioned ingredients to generate poly(vinyl alcohol)-based nanoparticles (NPs) using the single emulsion technique. Then the NPs were coated with F127 and F127-folate by simple incubation for five days. The nanoparticles have the hydrodynamic size of approx. 250 nm with negative charge. Similar to chlorambucil and IR780, iron oxide loadings were observed for all three kinds of NPs. The release of chlorambucil was quicker at pH 5.4 than at pH 7.4 at 37 °C. The F127@NPs and F127-folate@NPs demonstrated much greater cell uptake and toxicity up to 72 h after incubation. Our in vitro results of F127@NPs and F127-folate@NPs have demonstrated the ability of these systems to serve as medication and imaging agent carriers for cancer treatment and diagnostics, respectively.